Annomontine

Annomontine

SCHEMBL2994062

Nc1nccc(-c2nccc3c2[nH]c2ccccc23)n1

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 12/20 0.61
HTR2B P41595 3/20 0.61
HTR5A P47898 3/20 0.61
IDO1 P14902 4/20 0.60
BCHE P06276 2/20 0.59
HTR2C P28335 1/20 0.56
PDE5A O76074 1/20 0.54
CDK5 Q00535 2/20 0.54
CDK5R1 Q15078 2/20 0.54
CLK1 P49759 1/20 0.54
GSK3B P49841 1/20 0.54
DYRK1A Q13627 1/20 0.54
MAP3K14 Q99558 1/20 0.54
CCNB2 O95067 1/20 0.53
CDK1 P06493 1/20 0.53
CCNB1 P14635 1/20 0.53
CCNA2 P20248 1/20 0.53
CDK2 P24941 1/20 0.53
CCNA1 P78396 1/20 0.53
CCNB3 Q8WWL7 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27817460 0.82 TDO2 (0.80) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL12938247 0.80 TDO2 (0.67) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL23098942 0.80 HTR2B (0.61) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL29693816 0.80 HTR2B (0.61) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL28066961 0.79 TDO2 (0.70) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL28811802 0.78 BCHE (0.69) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL29891581 0.77 HTR2B (0.65) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL24105915 0.76 TDO2 (1.00) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL30431392 0.76 TDO2 (1.00) TDO2HTR2BHTR5AIDO1BCHE
SCHEMBL1798020 0.76 TDO2 (0.64) TDO2HTR2BHTR5AIDO1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150150770-A1 METHODS OF TREATING SKIN TRACIE MARTYN INTERNATIONAL INC (US) 2015-06-04 US disclosed
US-20140155961-A1 METHODS OF TREATING SKIN Tracie Martyn International, Inc. (US) 2014-06-05 US disclosed
US-20100272790-A1 Methods of Treating Skin TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-10-28 US disclosed
US-7776915-B2 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-08-17 US disclosed
EP-1360186-B1 CARBOLINE DERIVATIVES LILLY ICOS LLC (US) 2006-11-22 EP disclosed
US-20060216251-A1 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140155961-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT TDO2 2587/4885HTR2B 3442/4885HTR5A 2786/4885
US-20100272790-A1 Methods of Treating Skin CUTA, LIPA, DLAT TDO2 2587/4885HTR2B 3442/4885HTR5A 2786/4885
US-20150150770-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT TDO2 2587/4885HTR2B 3442/4885HTR5A 2786/4885
US-20060216251-A1 Topical formulations and methods of use CPT1B, SLC25A20, CPT1A TDO2 2305/4885HTR2B 2961/4885HTR5A 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.